SAN ANTONIO, TEXAS—The UK TACT2 trial, looking at over 4 000 patients with early breast cancer, has confirmed that modern chemotherapy is very effective, and continues to contribute to very high cure
SAN ANTONIO, TEXAS—The UK TACT2 trial, looking at over 4 000 patients with early breast cancer, has confirmed that modern chemotherapy is very effective, and continues to contribute to very high cure rates. Professor David Cameron of Edinburgh University explains the importance of this study.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/121206DavidCameronPODCASTLoRes.mp3]